Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Stock Short Interest Falls 52.5%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totaling 13,144 shares, a drop of 52.5% from the August 31st total of 27,645 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 422,623 shares, the days-to-cover ratio is currently 0.0 days.

Oncotelic Therapeutics Stock Up 1.3%

Oncotelic Therapeutics stock traded up $0.00 during midday trading on Wednesday, reaching $0.02. The stock had a trading volume of 76,102 shares, compared to its average volume of 283,895. The firm’s fifty day simple moving average is $0.03 and its 200-day simple moving average is $0.04. Oncotelic Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.11. The stock has a market capitalization of $10.86 million, a P/E ratio of 0.04 and a beta of -0.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.08 and a current ratio of 0.08.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel therapies for cancer and other serious diseases. The company’s research platform emphasizes RNA-based therapeutics and targets biological pathways involved in tumor growth, immune response, and disease progression.

Its principal investigational product is OT-101, also known as trabedersen, an antisense oligonucleotide designed to inhibit transforming growth factor beta 2 (TGF-?2). Oncotelic has studied OT-101 in several oncology settings, including brain and other solid tumors.